[Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate].
Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction > 2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89 +/- 9.45 (mean +/- SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44 +/- 2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000 mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (T0) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p < 0.001), D-Pyr - 34.96% (p < 0.001), NTX - 50.9% (p < 0.001). These preliminary data show that neridronate may be considered an useful agent for the treatment of GIOP in rheumatic patients.
Sezione di Reumatologia, Dipartimento Medicina Interna, Nuovo Ospedale S.Giovanni di Dio, ASL 10, Firenze. maubenucci@tiscali.it
Maurizio
M
Benucci
Stefano
S
Dolenti
Gianantonio
G
Saviola
Mariangela
M
Manfredi
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001862:Bone Resorption / Q000175:diagnosis / Q000188:drug therapy*; D002118:Calcium / Q000008:administration & dosage; D003627:Data Interpretation, Statistical; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy*; D011111:Polymyalgia Rheumatica / Q000188:drug therapy; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage
D004164:Diphosphonates; D005938:Glucocorticoids; D014807:Vitamin D; C053389:6-amino-1-hydroxyhexane-1,1-diphosphonate; D002118:Calcium